Ipsen is casting a wider BD net under new CEO Loew

With a pipeline heavy on line extensions and its bestseller headed toward a patent cliff, new Ipsen CEO David Loew is doubling down on the mid-cap biopharma’s commitment to external innovation. But this time, Ipsen will be looking for programs across a broader range of indications and with a focus on mid-sized, rather than blockbuster, opportunities. 

Tipping the scales towards external innovation isn’t a new idea for Ipsen Group (Euronext:IPN)...